|
294 Companies |
|
490 Products |
|
490 Products |
|
198 Mechanisms of Action |
|
25 Trials |
|
7787 News |
|
| «12...144145146147148149150151152153154...156157» |
- New P1/2 trial: MonoPepT1De: Safety Study to Assess Whether Proinsulin Peptide Injections Can Slow or Stop the Body Damaging Its Own Insulin-making Cells in the Pancreas in Patients Newly Diagnosed With Type 1 Diabetes (clinicaltrials.gov) - Feb 20, 2012
P1/2, N=24, Active, not recruiting, Sponsor: Cardiff University
- | Victoza (liraglutide) / Novo Nordisk
New P1 trial: The Effect of Liraglutide Adjunct to Insulin on Glucagon Response to Hypoglycaemia in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Feb 20, 2012
P1, N=45, Completed, Sponsor: Novo Nordisk
- Trial completion, Discordant: ARMS: AT RISK FOR MS - Clinical Conversion of Female Monozygotic Twins Discordant for CIS/MS (clinicaltrials.gov) - Feb 20, 2012
P=N/A, N=3, Completed, Sponsor: The University of Texas Health Science Center, Houston
Active, not recruiting --> Completed
- Promacta (eltrombopag) / Novartis
Enrollment open: Promacta Pregnancy Registry (clinicaltrials.gov) - Feb 19, 2012
P=N/A, N=1, Recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Active, not recruiting --> Recruiting
- | dalfampridine / Generic mfg.
New P2 trial: An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS) (clinicaltrials.gov) - Feb 16, 2012
P2, N=20, Completed, Sponsor: Acorda Therapeutics
- Tavalisse (fostamatinib) / Rigel
Enrollment change: Effects of Administration of Fostamatinib on Blood Concentrations of an Oral Contraceptive in Healthy Female Subjects (clinicaltrials.gov) - Feb 16, 2012
P1, N=22, Completed, Sponsor: AstraZeneca
Active, not recruiting --> Recruiting N=56 --> 22
- | Tavalisse (fostamatinib) / Rigel
Trial completion: Effects of Administration of Fostamatinib on Blood Concentrations of an Oral Contraceptive in Healthy Female Subjects (clinicaltrials.gov) - Feb 16, 2012
P1, N=22, Completed, Sponsor: AstraZeneca
N=56 --> 22 Recruiting --> Completed
- |||| BIIB023 / Biogen
Enrollment open: ATLAS: BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis (clinicaltrials.gov) - Feb 15, 2012
P2, N=300, Recruiting, Sponsor: Biogen Idec
Recruiting --> Completed Not yet recruiting --> Recruiting
- Stem cell educator therapy / Sinobioway
Enrollment change: Stem Cell Educator Therapy in Type 2 Diabetes (clinicaltrials.gov) - Feb 15, 2012
P1/2, N=25, Completed, Sponsor: University of Illinois at Chicago
Not yet recruiting --> Recruiting N=100 --> 25
- ||| Truxima (rituximab-abbs) / Indukern, Teva, Mundipharma, Celltrion, Nippon Kayaku
New P1 trial: Demonstrate the Equivalence of CT-P10 to MabThera With Respect to the Pharmacokinetic Profile in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Feb 15, 2012
P1, N=147, Active, not recruiting, Sponsor: Celltrion
- Stem cell educator therapy / Sinobioway
Trial completion: Stem Cell Educator Therapy in Type 2 Diabetes (clinicaltrials.gov) - Feb 15, 2012
P1/2, N=25, Completed, Sponsor: University of Illinois at Chicago
N=100 --> 25 Recruiting --> Completed
- ||||||| otelixizumab (ChAglyCD3) / GSK
Trial completion: Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1 (clinicaltrials.gov) - Feb 15, 2012
P3, N=272, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Completed Active, not recruiting --> Completed
- |||| otelixizumab (ChAglyCD3) / GSK
Trial completion: TRX4 Monoclonal Antibody in Type 1 Diabetes (T1 DM) (clinicaltrials.gov) - Feb 15, 2012
P2, N=100, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Active, not recruiting --> Completed
- thyroxine / Generic mfg.
Trial initiation date: Selenium Supplementation in Pregnancy (clinicaltrials.gov) - Feb 14, 2012
P4, N=150, Recruiting, Sponsor: University of Roma La Sapienza
Active, not recruiting --> Completed Initiation date: Nov 2011 --> Apr 2012
- thyroxine / Generic mfg.
Enrollment change: Selenium Supplementation in Pregnancy (clinicaltrials.gov) - Feb 14, 2012
P4, N=150, Recruiting, Sponsor: University of Roma La Sapienza
Initiation date: Nov 2011 --> Apr 2012 N=250 --> 150
- ||||| New P4 trial, Patient reported outcomes: Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC) (clinicaltrials.gov) - Feb 14, 2012
P4, N=313, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
- | Epratucyn (epratuzumab) / Gilead
New P2 trial: Open Label Extension Study of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Subjects (clinicaltrials.gov) - Feb 14, 2012
P2, N=17, Active, not recruiting, Sponsor: UCB, Inc.
- Tysabri (natalizumab) / Biogen, Royalty
Trial completion: NAPMS: Natalizumab Treatment of Progressive Multiple Sclerosis (clinicaltrials.gov) - Feb 14, 2012
P2, N=24, Completed, Sponsor: Rigshospitalet, Denmark
N=250 --> 150 Active, not recruiting --> Completed
- Trial initiation date: Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy (clinicaltrials.gov) - Feb 14, 2012
P=N/A, N=5, Terminated, Sponsor: Centre Hospitalier Universitaire de N?mes
Active, not recruiting --> Completed Initiation date: May 2011 --> Sep 2011
- ||| Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Enrollment change: BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes (clinicaltrials.gov) - Feb 14, 2012
P2, N=70, Completed, Sponsor: Bristol-Myers Squibb
Initiation date: May 2011 --> Sep 2011 N=90 --> 70
- ||| Clinical: Special Survey for Patients With Type 1 or Type 2 Diabetes (clinicaltrials.gov) - Feb 14, 2012
P=N/A, N=1582, Completed, Sponsor: Novo Nordisk
- | BIAsp 30 (biphasic insulin aspart 30/70 biosimilar) / Novo Nordisk
New P1 trial: Comparison of the Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30, 50, 70 and Insulin Aspart in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Feb 14, 2012
P1, N=32, Completed, Sponsor: Novo Nordisk
- dexamethasone injection / Generic mfg.
New P1 trial: Function of Regulatory T Cells Improved by Dexamethasone in Graves' Patients (clinicaltrials.gov) - Feb 14, 2012
P1, N=50, Completed, Sponsor: Xiao-Ming Mao
- Enrollment closed: Evaluation of Accu-Chek DiaPort, a Port System for Continuous Intraperitoneal Insulin Infusion, in Patients With Type I Diabetes (clinicaltrials.gov) - Feb 14, 2012
P=N/A, N=12, Active, not recruiting, Sponsor: Hoffmann-La Roche
N=90 --> 70 Recruiting --> Active, not recruiting
- Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial completion: Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D) (clinicaltrials.gov) - Feb 14, 2012
P4, N=26, Completed, Sponsor: University of Colorado, Denver
Recruiting --> Active, not recruiting Enrolling by invitation --> Completed
- Enrollment change: The Biodistribution of 1-L-(2 Deoxy-2,- 18 Fluoroarabinofuranosyl) Cytosine ([18F]L-FAC) in Healthy Subjects and Patients With Cancer, Autoimmune and Inflammatory Diseases (clinicaltrials.gov) - Feb 13, 2012
P=N/A, N=1, Completed, Sponsor: Jonsson Comprehensive Cancer Center
Enrolling by invitation --> Completed N=30 --> 1
- Trial completion: The Biodistribution of 1-L-(2 Deoxy-2,- 18 Fluoroarabinofuranosyl) Cytosine ([18F]L-FAC) in Healthy Subjects and Patients With Cancer, Autoimmune and Inflammatory Diseases (clinicaltrials.gov) - Feb 13, 2012
P=N/A, N=1, Completed, Sponsor: Jonsson Comprehensive Cancer Center
N=30 --> 1 Recruiting --> Completed
- ibandronate sodium hydrate / Generic mfg.
Trial completion: Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus (clinicaltrials.gov) - Feb 9, 2012
P4, N=40, Completed, Sponsor: Chinese University of Hong Kong
Recruiting --> Completed Active, not recruiting --> Completed
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion, Combination therapy: Can Targeted Elimination of B-cell Depletion Therapy and/or Combination Therapy on Systemic Lupus Erythematosus (clinicaltrials.gov) - Feb 9, 2012
P2, N=20, Completed, Sponsor: Chinese University of Hong Kong
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Avonex (recombinant IFN-β-1a) / Biogen, Zinbryta (daclizumab) / Biogen, AbbVie
Enrollment change, Monotherapy: Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov) - Feb 8, 2012
P3, N=1800, Active, not recruiting, Sponsor: Biogen Idec
Active, not recruiting --> Completed N=1500 --> 1800
- ||| Trial completion, HEOR: Economic Burden in Adult Patients Diagnosed With Rheumatoid Arthritis (RA) Receiving Treatment With Biologic Disease-modifying Antirheumatic Drugs (bDMARDs) (clinicaltrials.gov) - Feb 8, 2012
P=N/A, N=695, Completed, Sponsor: Bristol-Myers Squibb
N=1500 --> 1800 Active, not recruiting --> Completed
- |||| Epratucyn (epratuzumab) / Gilead
Trial completion: Open-label Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease (clinicaltrials.gov) - Feb 8, 2012
P2b, N=210, Completed, Sponsor: UCB, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Epratucyn (epratuzumab) / Gilead
Trial completion: Study of Epratuzumab in Systemic Lupus Erythematosus (clinicaltrials.gov) - Feb 8, 2012
P2, N=29, Completed, Sponsor: UCB, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | TAK-329 / Takeda
Trial completion: TAK-329 Glucose Clamp Study (clinicaltrials.gov) - Feb 8, 2012
P1, N=37, Completed, Sponsor: Takeda
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Humira (adalimumab) / Eisai, AbbVie
Trial completion: Predictors of the Response to Adalimumab in Rheumatoid Arthritis (clinicaltrials.gov) - Feb 7, 2012
P4, N=200, Completed, Sponsor: University Hospital, Rouen
Active, not recruiting --> Completed Recruiting --> Completed
- Januvia (sitagliptin) / Merck (MSD)
New P4 trial: Sitagliptin Dose Determination Study (clinicaltrials.gov) - Feb 7, 2012
P4, N=30, Recruiting, Sponsor: Albert Einstein College of Medicine of Yeshiva University
- |||| CCX354 / Amgen
Trial completion: CARAT-2: A Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy (clinicaltrials.gov) - Feb 7, 2012
P2, N=159, Completed, Sponsor: ChemoCentryx
Recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: ITOPOS: Importance in Type 1 Diabetes Patients of an Optimized Control of Post-Prandial Glycaemia on Oxidant Stress Prevention (clinicaltrials.gov) - Feb 7, 2012
P=N/A, N=50, Completed, Sponsor: Centre d
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Orencia (abatacept) / BMS
Trial completion, P3 data, Monotherapy: Phase IIIB Subcutaneous Abatacept Monotherapy Study (clinicaltrials.gov) - Feb 6, 2012
P3, N=100, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: Evaluation of [18F] FEPPA and PET Imaging as a Marker of Inflammation in Subjects With Neurological Conditions (clinicaltrials.gov) - Feb 6, 2012
P1, N=3, Completed, Sponsor: Institute for Neurodegenerative Disorders
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Enbrel (etanercept) / Pfizer, Amgen
Trial completion: Registry of Etanercept Use in Patients With Rheumatoid Arthritis in Clinical Practice in Taiwan (clinicaltrials.gov) - Feb 6, 2012
P=N/A, N=441, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed Recruiting --> Completed
- |||| Enbrel (etanercept) / Pfizer, Amgen
Trial completion, Combination therapy: PRESERVE: Study Comparing Etanercept in Combination With Methotrexate in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Feb 6, 2012
P4, N=834, Completed, Sponsor: Pfizer
Recruiting --> Completed Active, not recruiting --> Completed
- ||||| inactivated VZV vaccine (V212) / Merck (MSD)
New P2 trial: A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Adults With Autoimmune Disease (V212-009) (clinicaltrials.gov) - Feb 5, 2012
P2, N=354, Completed, Sponsor: Merck Sharp & Dohme Corp.
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion: Rituximab in Rheumatoid Arthritis Lung Disease (clinicaltrials.gov) - Feb 5, 2012
P3, N=10, Completed, Sponsor: Eric Matteson
Active, not recruiting --> Completed Active, not recruiting --> Completed
- atacicept (VT-001) / Vera Therap
P2 data, Enrollment change: ATAMS ext: Atacicept in Multiple Sclerosis Extension Study, Phase II (clinicaltrials.gov) - Feb 2, 2012
P2, N=68, Terminated, Sponsor: EMD Serono
Active, not recruiting --> Completed N=250 --> 68
- |||| Trial completion: TERIVA: Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide (clinicaltrials.gov) - Feb 2, 2012
P2, N=128, Completed, Sponsor: Sanofi
N=250 --> 68 Active, not recruiting --> Completed
- |||| ceralifimod (ONO 4641) / Ono Pharma
Trial completion: DreaMS: A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov) - Feb 2, 2012
P2, N=407, Completed, Sponsor: Ono Pharma USA Inc
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Aspart-PH20 (insulin aspart/rHuPH20) / Halozyme, Lispro-PH20 (insulin lispro/rHuPH20) / Halozyme
New P4 trial: Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase (clinicaltrials.gov) - Feb 2, 2012
P4, N=25, Active, not recruiting, Sponsor: Halozyme Therapeutics
- Enrollment change: Effects Of Prednisolone On Rheumatoid Arthritis Patients (clinicaltrials.gov) - Feb 1, 2012
P=N/A, N=32, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed N=45 --> 32
- || Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
New P3 trial, Combination therapy: rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP (clinicaltrials.gov) - Feb 1, 2012
P3, N=240, Recruiting, Sponsor: Shandong University